Lyndsey Johnson

Southmead Hospital, North Bristol NHS Trust

Papers

4

Total Citations

366

H-Index

4

About

Lyndsey Johnson is a leading urologic surgeon and researcher whose work centers on optimizing surgical outcomes for patients with bladder and prostate cancers through rigorous clinical trials and health economics. Her most impactful contribution is a landmark 2022 study in the *Journal of the American Medical Association* (320 citations), which demonstrated that robot-assisted radical cystectomy with intracorporeal urinary diversion does not significantly reduce 90-day morbidity or mortality compared to open surgery for bladder cancer—a finding that has reshaped surgical decision-making. Johnson further advanced the field by evaluating the cost-effectiveness of this robotic approach, showing that while it offers comparable outcomes, its value to payers remains uncertain (26 citations). She is also the principal investigator of the NeuroSAFE PROOF trial, a multi-center randomized controlled study exploring whether intraoperative nerve-sparing assessment during robotic prostatectomy can better preserve erectile function and continence in men with localized prostate cancer. Her work bridges surgical innovation with patient-centered outcomes and economic analysis, making her a pivotal voice in evidence-based urologic oncology.

Research Focus

Key Achievements

4
H-Index
4
Papers
366
Total Citations
92
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2022 (3 Papers)
🤝 Key Collaborators: 93
🏛 Institutions: Southmead Hospital, North Bristol NHS Trust

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago